Biotechnology · Nasdaq

ALNYAlnylam Pharmaceuticals, Inc.

Last close
$165.04 +5.4%
52-week range
$149.18 to $479.79
Market cap
$22.1B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$3.71B
+65% vs FY24
Net income
$314M
+213% vs FY24
Free cash flow
$465M
+1,193% vs FY24
Net cash
$2.91B
Cash $2.91B, no debt reported

Stock price

+291% since Dec 2016

Valuation vs its own 10 years

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
n/a
n/a: No earnings
Median 373x, range 177x to 569x
Price / sales
n/a
n/a: Not meaningful (negative or missing)
Median 28.2x, range 9.4x to 136x
EV / EBITDA
n/a
n/a: Not meaningful (negative or missing)
Median 178x, range 95.5x to 187x
Price / free cash flow
n/a
n/a: Not meaningful (negative or missing)
Median 261x, range 96.6x to 2,202x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
n/aNo earnings
Earnings yield
n/a
Price / sales
n/a
Price / book
6.1x
Price / operating cash flow
n/a
EV / EBITDA
n/a
EV / sales
n/a
Free cash flow yield
n/a

n/a: Not reported

Profitability

Gross margin
n/a
Operating margin
n/a
Net margin
n/a
Return on equity
73.5%
Return on capital
n/a

n/a: Not reported

Growth per year

Revenue, 3 years
+53.0%
Revenue, 5 years
+49.8%
Revenue, 9 years
+62.4%
EPS, 3 years
n/aNot meaningful (a loss in the window)

Balance sheet

Cash and investments
$3.59B
Total debt
n/a
Net cash
$3.59B
Debt / equity
n/a
Current ratio
2.48x

n/a: No debt reported

Shares and dividend

Shares outstanding
134M
Share count, 5 years
+17.1%
Beta, 1 year
0.54
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $1.46B
RevenueNet income
Gross profitLatest quarter $1.10B
EBITDALatest quarter $360M
Margins75 / 24 / 149%
GrossOperatingNet
Earnings per shareLatest quarter $15.72
Cash flowLatest quarter $341M
OperatingCapexFree
Cash vs debtLatest quarter $3.59B
Cash and investmentsTotal debt
P/E historyNow n/a
P/E, median 373x dashed
P/S historyNow n/a
P/S, median 28.2x dashed

Where the revenue comes from

Amvuttra went from 9% to 62% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

AmvuttraCollaborationsGIVLAARIOXLUMORoyaltyONPATTRO
FY22
9%13%17%54%
$1.04B
FY23
31%30%12%19%
$1.83B
FY24
43%23%11%11%
$2.25B
FY25
62%15%8%
$3.71B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Amvuttra$2.31B62.3%+138%
Collaborations$553M14.9%+8%
GIVLAARI$308M8.3%+21%
OXLUMO$191M5.2%+15%
Royalty$174M4.7%+90%
ONPATTRO$173M4.7%-32%

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
ALNY Alnylam Pharmaceuticals, Inc. $22.1B n/a n/aNo earningsn/a No earnings

The company

Sector
Health Care
Industry
Biotechnology
Founded
2002
Headquarters
Cambridge, MA
Fiscal year ends
December
Website
alnylam.com

What it does

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about ALNY.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 513 active funds. Crowd level: quiet.

Open the Smart money tab